Human insulin-like growth factors binding protein 2,IGFBP-2 ELISA Kit

Code CSB-E04588h
Size 96T,5×96T,10×96T
Trial Size 24T ELISA Kit Trial Size (Only USD$150/ kit)
* The sample kit cost can be deducted from your subsequent orders of 96T full size kits of the same analyte at 1/5 per kit, until depleted in 6 months. Apply now
Promotion 25% Off Above 3 its (96T) Per Item
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Target Name
insulin-like growth factor binding protein 2, 36kDa
Alternative Names
BP 2 ELISA Kit; BP2 ELISA Kit; IBP 2 ELISA Kit; IBP-2 ELISA Kit; IBP2 ELISA Kit; IBP2_HUMAN ELISA Kit; IGF binding protein 2 ELISA Kit; IGF BP53 ELISA Kit; IGF-binding protein 2 ELISA Kit; IGFBP 2 ELISA Kit; IGFBP-2 ELISA Kit; IGFBP2 ELISA Kit; IGFBP53 ELISA Kit; Insulin like growth factor binding protein 2 36kDa ELISA Kit; Insulin like growth factor binding protein 2 ELISA Kit; Insulin like growth factor-binding protein 2 precursor ELISA Kit; Insulin-like growth factor-binding protein 2 ELISA Kit
Uniprot No.
Homo sapiens (Human)
Sample Types
serum, plasma, tissue homogenates
Detection Range
0.78 ng/mL-50 ng/mL
0.195 ng/mL
Assay Time
Sample Volume
Detection Wavelength
450 nm
Research Area
Signal Transduction
Assay Principle
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
To assess the linearity of the assay, samples were spiked with high concentrations of human IGFBP-2 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
1:5Average %97
Range %91-105
1:10Average %95
Range %92-98
1:20Average %92
Range %86-99
1:40Average %94
Range %89-100
The recovery of human IGFBP-2 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample TypeAverage % RecoveryRange
Serum (n=5) 9689-101
EDTA plasma (n=4)9488-99
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
502.935 2.952 2.944 2.767
252.026 2.076 2.051 1.874
12.51.088 1.046 1.067 0.890
6.250.592 0.583 0.588 0.411
3.120.361 0.337 0.349 0.172
1.560.278 0.259 0.269 0.092
0.780.232 0.229 0.231 0.054
00.176 0.177 0.177  
and FAQs
Store at 2-8°C. Please refer to protocol.
Lead Time
3-5 working days

The product CSB-E04588h is a sandwich ELISA kit developed to measure concentrations of human IGFBP2 in serum, plasma, or tissue homogenates. This assay uses the sandwich enzyme immunoassay technique in combination with the enzyme-substrate chromogenic reaction to quantify the analyte in the sample. The color develops positively to the amount of IGFBP2 in samples. The color intensity is measured at 450 nm via a microplate reader.

IGFBP2 is considered a major regulator of IGFs bioavailability in the metabolic signaling pathway and controls the distribution, function, and activity of IGFs in the pericellular space. It is a developmentally regulated gene that is highly expressed in embryonic and fetal tissues and markedly decreases after birth. Abnormal overexpression of IGFBP2 is related to an aggressive phenotype of a broad range of human cancers, including glioma, ovarian, prostate, pancreatic, breast, lung, colorectal, melanoma, and liver cancer. High circulating IGFBP2 levels may serve as a useful diagnostic or prognostic tumor biomarker in many types of cancer and are closely linked to relapse and a poorer outlook for patients with cancer.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

(From Uniprot)
Inhibits IGF-mediated growth and developmental rates. IGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGFs on cell culture. They alter the interaction of IGFs with their cell surface receptors.
Gene References into Functions
  1. Following IGFBP2 knockdown using rAAV2-ZsGreen-shRNA-hIGFBP2, matrix metalloproteinase2 expression was significantly reduced in tumor tissues compared with that in rAAV2ZsGreenshRNAscramble treated tumor tissues. PMID: 29344663
  2. IGFBP2 overexpression increased the expression of p-p65 and nuclear p65, while IGFBP2 knockdown reduced the expression of p-p65 and nuclear p65. PMID: 29228449
  3. The associated effects appear to be mediated by inhibition of IGFBP-2 expression and stimulation of p21 expression. This suggests that simulated microgravity might represent a promising method to discover new targets for glioma therapeutic strategy. PMID: 28707224
  4. these results suggest that IGFBP2 plays an important role in promoting tumorigenesis, through estrogen and ERalpha signaling pathway. PMID: 28410230
  5. patients with low IGFBP2 expressiondisplay a clear advantage in overall and disease-free survival, whereas those with high IGFBP2 expressionhave worse median survival than IDH-wildtype patients. PMID: 27852048
  6. The interaction of IGFBP2 and p63 might account for the pathogenesis of rhabdomyosarcoma tumors. PMID: 28129571
  7. Co-ordinated and reciprocal alteration in IGFBP-2 and -5 expression may play a role in the acquisition of endocrine resistance in breast cancer. PMID: 27050076
  8. We verified that NFIA binds to the IGFBP2 promoter and transcriptionally enhances IGFBP2 expression levels. We identified that NFIA-mediated IGFBP2 signaling pathways are involved in miR-302b-induced glioma cell death. PMID: 28323865
  9. Insulin-like growth factor binding protein 2 potentiates glioblastoma tumor growth by the activation of the beta-catenin pathway through its C-terminal domain, and their coexpression possibly contributes to worse patient prognosis. PMID: 27044294
  10. mechanistic investigations defined insulin-like growth factor binding protein 2 (IGFBP2)as a direct and functional downstream target of microRNA-592, which was involved in the microRNA-592-mediated tumor-suppressive effects in glioma cells. PMID: 28718372
  11. IGFBP2 and IGFBP3 may serve as compensatory biomarkers for CA19-9. Early diagnosis with this marker combination may improve the prognosis of invasive ductal adenocarcinoma of pancreas patients. PMID: 27579675
  12. In human whole blood cells, methylation of IGFBP2 at the homologous CpG site was increased in obese men with impaired glucose tolerance. In conclusion, our data show that increased methylation of hepatic Igfbp2 during infancy predicts the development of fatty liver later in life and is linked to deterioration of glucose metabolism. PMID: 27126637
  13. Data suggest that circulating insulin-like growth factor-binding protein 2 (IGFBP2) has potential as a biomarker predicting prognosis for gastric cancer patients. PMID: 28036255
  14. Together, this study validated that T-2 toxin exposure might promote the progression of KBD by inducing chondrocyte injury, suppressing matrix synthesis and accelerating cellular catabolism through IGFBP2. Therefore, this research will elucidate a new insight about how T-2 toxin participate in the pathogenesis of KBD. PMID: 27416762
  15. IGFBP2 protein levels are altered in type 2 diabetes mellitus patients and associated with cardiovascular disease risk factors. PMID: 28179448
  16. The monoclonal gammopathy of undetermined significance and multiple myeloma patients displayed a significant increase in intact IGFBP-2 and decrease in intact IGFBP-3 in the circulation compared to control individuals. PMID: 27111220
  17. In patients with malignant and borderline ovarian tumors, the level of IGFBP-2 was higher than in healthy women and in patients with benign ovarian tumors. PMID: 27165066
  18. IGFBP2 and SOCS3 were up-regulated in Kashin-Beck disease chondrocytes and decreased with increasing selenium concentrations. IGFBP2 expressed highest in the middle zone of KBD cartilage, SOCS3 expressed higher in the middle and deep zone. IGFBP2 and SOCS3 may be the biomarkers for KBD diagnosis and evaluating the effect of selenium supplement. PMID: 27099071
  19. There was a positive correlation between the IGFBP2 levels of and those of inflammatory mediators in HIV Infections. PMID: 25890304
  20. IGFBP-2 overexpression in HUVECs promoted endothelial progenitor cells(EPC)-endothelial adhesion. The RGD motif in its C-domain is required for interaction with integrin alpha5beta1. PMID: 26076738
  21. Serum IGFBP2 reflects disease activity and renal pathology changes in lupus nephritis. PMID: 26616478
  22. Data show that modulation of insulin like growth factor binding protein 2 (IGFBP2) expression affects proliferation, motility, and chemosensitization of eophageal adenocarcinoma (EAC) cells in a serum-dependent manner. PMID: 26317790
  23. Identification of a novel tumor-promoting function for IGFBP2 of activating EGFR/STAT3 signaling and facilitating EGFR accumulation in the nucleus, thereby deregulating EGFR signaling by two distinct mechanisms. PMID: 25893308
  24. that age-specific cognitive decline may be moderated by IGF-BP2 PMID: 26043140
  25. Serum IGFBP2 was increased in patients with hepatocellular carcinoma compared to healthy controls, but lower than in patients with liver cirrhosis. PMID: 26068014
  26. The expression levels of maspin were lower in the cisplatin-resistant tissue and cells, and was enhanced by IGFBP-2 inhibition. PMID: 26080829
  27. Insulin-like growth factor binding protein 2 is strongly associated with restoration of keratocyte phenotype in HCFs. PMID: 26559475
  28. Elevated serum IGFBP2 levels might play a role in the postnatal growth retardation phenotype of Pallister-Killian syndrome. PMID: 25900123
  29. IGFBP-2 secreted by mature adipocytes plays a key role in promoting the metastatic ability of MCF-7 breast cancer cells PMID: 25747684
  30. These results implicate TRIB3 and IGFBP2, both of which are known to be overexpressed in several types of cancers, as pro-survival modulators of cell viability in nutrient-deficient microenvironments. PMID: 26094770
  31. IGFBP-2 may have a role in metabolic syndrome and is independently associated with VLDL triglycerides PMID: 25463100
  32. Report changes in serum levels of protein molecular forms of insulin-like growth factor binding protein-2 with age. PMID: 25106097
  33. Low IGFBP2 expression is associated with adrenocortical carcinoma. PMID: 24833102
  34. Elevated plasma IGFBP-2 levels after combined postoperative radiotherapy and chemotherapy in elderly glioblastoma patients correlate with poor Karnofsky performance status score and predicts poor prognosis. PMID: 24690948
  35. The amount of IGFBP-2 monomer increased in sera from all studied patients compared to controls, whereas the amount of IGFBP-2/alpha2M complexes most often decreased, being significantly reduced in patients with pancreas, colon, breast or ovary tumor. PMID: 25746666
  36. A combined profile of preoperative IGFBP-2, GFAP, and YKL-40 plasma levels could serve as an additional diagnostic tool for patients with inoperable brain lesions suggestive of Glioblastoma multiforme. PMID: 25139333
  37. Constitutive IGFBP2 downregulation may represent a novel mechanism for acquired resistance to IGF1R therapeutic antibody in vivo. PMID: 24292683
  38. Serum IGFBP2 and MSLN are weak diagnostic classifiers individually, but may be useful in a diagnostic biomarker panel for pancreatic cancer. PMID: 24308545
  39. two IGFBP2 heparin-binding domains contribute differentially to 2- or 3-carbon O-sulfated glycosaminoglycans binding in free IGFBP2 and the IGF2/IGFBP2 protein complex. PMID: 24604839
  40. Increased serum concentration significantly and independently associated with long-term cardiovascular disease mortality in patients with lower-extremity peripheral artery disease PMID: 24548188
  41. Exogenous IGFBP-2 induces proliferation, invasion, and chemoresistance in glioma cells via integrin-beta1/ERK signaling. PMID: 25093489
  42. IGFBP2 is a critical cell-autonomous factor that promotes the survival and migration of acute leukemia cells. PMID: 24191913
  43. insulin-like growth factors bound to IGFBP-3 remain in the circulation, whereas those bound to IGFBP-2 freely reach target tissues. PMID: 24051179
  44. High IGFBP-2 gene expression is asssociated with cytomegalovirus positive glioblastoma multiforme. PMID: 24352760
  45. the IGFBP2/FAK pathway is causally associated with dasatinib resistance. PMID: 24130049
  46. IGFBP2 overexpression is associated with metastasis and poor survival in NSCLC patients. PMID: 24682597
  47. Insulin-like growth factor binding protein-2 level is increased in blood of lung cancer patients and associated with poor survival. PMID: 24069370
  48. IGFBP-2 in complex with alpha2 macroglobulin was 2.5 times lower in cancer patients. PMID: 24275430
  49. IGFBP-2 possesses a functional nuclear localization signal sequence and IGFBP-2 actively translocates into the nucleus by a classical nuclear import mechanism, involving formation of IGFBP-2 complexes with importin-alpha. PMID: 23435424
  50. Increased glucose concentrations inhibited the efficacy of docetaxel at inducing apoptosis, which was associated with increased IGFBP2 production as a result of glucose-induced acetylation of histones bound to the IGFBP2 promoter. PMID: 23959956

Show More

Hide All

Subcellular Location
Database Links

HGNC: 5471

OMIM: 146731

KEGG: hsa:3485

STRING: 9606.ENSP00000233809

UniGene: Hs.438102

Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
7505 Fannin St Ste 610-322 Houston, TX 77054, USA
Join Us with

Leave a message

check code
© 2007-2023 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1